Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
- 1 October 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 30 (4) , 614-616
- https://doi.org/10.1128/aac.30.4.614
Abstract
Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa. Patients were studied in a steady state on a dosage of 500 mg every 8 h. Peak levels in serum ranged from 1.27 to 5.6 mg/liter (mean, 3.16 +/- 1.27), and absorption was rapid, the time to peak concentration ranging from 0.5 to 3.0 h (mean, 1.5 +/- 0.9). The antibiotic penetrated sputum well, achieving areas under the curve of approximately 46% of those obtained in serum.This publication has 6 references indexed in Scilit:
- Determination of Ciprofloxacin (Bay o 9867) in Biological Fluids by High-Performance Liquid ChromatographyJournal of Liquid Chromatography, 1985
- In-vitro studies with ciprofloxacin, a new 4-quinolone compoundJournal of Antimicrobial Chemotherapy, 1984
- Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.Thorax, 1984
- Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosisRespiratory Medicine, 1983
- Pharmacokinetics and tissue penetration of ciprofloxacinAntimicrobial Agents and Chemotherapy, 1983
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983